- Home
- TOL vs ILMN Comparison
TOL vs ILMN Comparison
Compare TOL & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOL
- ILMN
- Stock Information
- Founded
- TOL 1967
- ILMN 1998
- Country
- TOL United States
- ILMN United States
- Employees
- TOL N/A
- ILMN N/A
- Industry
- TOL Homebuilding
- ILMN Medical Specialities
- Sector
- TOL Consumer Discretionary
- ILMN Health Care
- Exchange
- TOL Nasdaq
- ILMN Nasdaq
- Market Cap
- TOL 13.6B
- ILMN 15.9B
- IPO Year
- TOL N/A
- ILMN 2000
- Fundamental
- Price
- TOL $105.58
- ILMN $79.34
- Analyst Decision
- TOL Buy
- ILMN Buy
- Analyst Count
- TOL 16
- ILMN 18
- Target Price
- TOL $144.93
- ILMN $141.94
- AVG Volume (30 Days)
- TOL 1.8M
- ILMN 2.3M
- Earning Date
- TOL 05-20-2025
- ILMN 05-01-2025
- Dividend Yield
- TOL 0.95%
- ILMN N/A
- EPS Growth
- TOL 12.43
- ILMN N/A
- EPS
- TOL 14.58
- ILMN N/A
- Revenue
- TOL $10,758,023,000.00
- ILMN $4,372,000,000.00
- Revenue This Year
- TOL $1.09
- ILMN $1.49
- Revenue Next Year
- TOL $4.76
- ILMN $5.03
- P/E Ratio
- TOL $7.24
- ILMN N/A
- Revenue Growth
- TOL 5.86
- ILMN N/A
- 52 Week Low
- TOL $101.50
- ILMN $77.55
- 52 Week High
- TOL $169.52
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- TOL 39.03
- ILMN 25.04
- Support Level
- TOL $103.00
- ILMN $83.50
- Resistance Level
- TOL $112.28
- ILMN $89.95
- Average True Range (ATR)
- TOL 3.41
- ILMN 2.85
- MACD
- TOL 0.73
- ILMN 0.69
- Stochastic Oscillator
- TOL 37.85
- ILMN 14.44
About TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US It has its headquarters in Horsham, Pennsylvania.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.